Diabetic Retinopathy Update: Best Practices in Referrals, Screening, and Treatments

By: Andrew A. Moshfeghi, MD, MBA (Moderator); Mark Dunbar, OD, FAAO; Roger A. Goldberg, MD, MBA; Veeral S. Sheth, MD, MBA, FACS; Frank G. Zheng, OD, MS

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

This continuing education activity captures content from a virtual roundtable discussion.

ACTIVITY DESCRIPTION
The overwhelming majority (85%) of comprehensive eye exams are conducted by optometrists. Diabetic retinopathy (DR) is the most common ocular complication of diabetes and is currently responsible for more than 10,000 new cases of blindness each year in the United States alone. This supplement highlights discussion topics among experts in the field and provides important education on caring for this patient demographic.

TARGET AUDIENCE
This certified CE activity is designed for optometrists who manage patients with diabetic eye conditions.

Expiration Date: Friday, June 30, 2023

Release Date: June 22, 2021

This activity is supported by an unrestricted educational grant from Regeneron and Carl Zeiss Meditec.

Learning Objectives

Upon completion of this activity, the participant should be able to:

Summarize the rise of diabetes and DR in the US population and the related impact on ocular health.
Understand effective screening strategies and imaging tools for diagnosing DR and diabetic macular edema (DME).
Identify which patients need early referral to a retina specialist based on their behavioral patterns, disease state, and/or other risk factors.
Identify and discuss how imaging devices may be able to provide earlier diagnosis of disease or disease progression.
Explain the latest treatment approaches to DR/DME.
Describe novel developments in DR screening.

Accreditation and Designation Statement

Participation Method

In order to obtain credit, complete the evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers: Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Andrew A. Moshfeghi, MD, MBA (Moderator)

Associate Professor of Clinical Ophthalmology Director of Clinical Trials
University of Southern California
Keck School of Medicine
Los Angeles, CA

Mark Dunbar, OD, FAAO

Director of Optometric Services
University of Miami
Miller School of Medicine
Bascom Palmer Eye Institute
Miami, FL

Roger A. Goldberg, MD, MBA

Vitreoretinal Specialist
Bay Area Retina Associates
Walnut Creek, CA
Volunteer Faculty
California Pacific Medical Center
Ophthalmology Residency
San Francisco, CA

Veeral S. Sheth, MD, MBA, FACS

Partner and Director of Clinical Trials
University Retina
Chicago, IL

Frank G. Zheng, OD, MS

Partner and Principle Optometrist
Lafayette Optometric Group
Lafayette, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Andrew A. Moshfeghi, MD, MBA, has had a financial interest has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Genentech, Graybug, Novartis, Ocular Therapeutix, Pr3vent, and Regeneron Pharmaceuticals. Grant/Research Support: Genentech, Novartis, and Regeneron Pharmaceuticals. Stock/Shareholder: Ocular Therapeutix, Prevent, and Placid.

Mark Dunbar, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Allergan, Carl Zeiss Meditec, Genentech, and Regeneron Pharmaceuticals.

Roger A. Goldberg, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Allergan, Apellis Pharmaceuticals, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan and Genentech.

Veeral S. Sheth, MD, MBA, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences and Genentech. Grant/Research Support: Alimera Sciences, Allergan, Chengdu Kanghong, DRCR, Genentech, Gyroscope, lonis, lveric Bio, NGM Blopharmaceuticals, Novartis, Regeneron Pharmaceuticals, SalutarisMD, SamChungDang, and Santen. Speaker’s Bureau: Genentech.

Frank G. Zheng, OD, MS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Iris Vision. Speaker’s Bureau: Bausch + Lomb.

The Evolve staff and planners have no financial relationships with commercial interests.
Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Modern Optometry, Regeneron Pharmaceuticals, or Carl Zeiss Meditec.